Transposase (truncated form)

A **truncated transposase** is a genetically engineered or proteolytically processed form of a transposase enzyme that lacks part of its normal amino acid sequence. In the well-studied Tn5 system, the truncated variant (sometimes called the "inhibitor") retains similar secondary and tertiary folding as the full-length enzyme but is functionally deficient, typically lacking full catalytic or DNA integration activity[2][1]. Instead, truncated transposases frequently act as dominant-negative inhibitors by forming nonproductive complexes with the active transposase or by dimerizing without enabling DNA transposition[2]. These truncated forms are widely used as research tools to dissect transposase domain function and to regulate transposon mobility, but they are not established drug or therapeutic targets[2]. Their biological significance is primarily experimental, and there is no evidence supporting clinical application, biomarker utility, or safety monitoring in humans. Key limitations: - **Not a canonical therapeutic target**: "Truncated transposase" is not the name of a naturally occurring gene, enzyme, or protein used in clinical therapeutics; it refers to an engineered variant mainly used in laboratory research. - **Information context-specific**: Details may vary depending on the transposase family (e.g., Tn5, piggyBac, Mu, etc.), but the truncated variant is generally non-functional or inhibitory and used for molecular biology investigations, not clinical medicine[2][3]. - **Naming issue**: The entry is unspecific without reference to the parent transposase family. "Truncated transposase" should not be treated as a distinct canonical entity, making **is_incorrect: true** in the context of a canonical therapeutic target.

Other names

Truncated transposaseTn5 truncated transposasetransposase inhibitor (specific for Tn5 context)

Inhibition of transposition by competitive inhibition or formation of nonproductive complexes with wild-type transposase